Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 20, 2019 - Issue 7-8
Submit an article Journal homepage
5,876
Views
24
CrossRef citations to date
0
Altmetric
Clinical Trials

A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis

Jeremy M. ShefnerDepartment of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA, ;Department of Neurology, University of Arizona, Phoenix, AZ, USA, Correspondence[email protected]
View further author information
,
Merit E. CudkowiczDepartment of Neurology, Neurological Clinical Research Institute, Massachusetts General Hospital, Boston, MA, USA, View further author information
,
Orla HardimanAcademic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland, View further author information
,
Bettina M. CockroftCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Jacqueline H. LeeCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Fady I. MalikCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Lisa MengCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Stacy A. RudnickiCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Andrew A. WolffCytokinetics, Inc, South San Francisco, CA, USA, and View further author information
,
Jinsy A. AndrewsThe Neurological Institute, Columbia University, New York, NY, USAView further author information
& on behalf of the VITALITY-ALS STUDY GROUP show all
Pages 584-594 | Received 08 Feb 2019, Accepted 22 Apr 2019, Published online: 13 May 2019

References

  • Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol. 2006;5:140–7.
  • Goyal NA, Mozaffar T. Respiratory and nutritional support in amyotrophic lateral sclerosis. Curr Treat Options Neurol. 2014;16:270.
  • Rooney J, Byrne S, Heverin M, Corr B, Elamin M, Staines A, et al. Survival analysis of Irish amyotrophic lateral sclerosis patients diagnosed from 1995-2010. PLoS One. 2013;8:e74733.
  • Shefner JM, Watson ML, Meng L, Wolff AA, The Neals/Cytokinetics STUDY Team. A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:574–81.
  • Shefner JM. Muscle as a therapeutic target in amyotrophic lateral sclerosis. Exp Neurol. 2009;219:373–5.
  • Hwee DT, Kennedy A, Ryans J, Russell AJ, Jia Z, Hinken AC, et al. Fast skeletal muscle troponin activator tirasemtiv increases muscle function and performance in the B6SJL-SOD1G93A ALS mouse model. PLoS One. 2014;9:e96921.
  • Russell AJ, Hartman JJ, Hinken AC, Muci AR, Kawas R, Driscoll L, et al. Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseases. Nat Med. 2012;18:452–5.
  • Shefner JM, Wolff AA, Meng L, Bian A, Lee J, Barragan D, on behalf of the BENEFIT-ALS study group, et al. A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:426–35.
  • Shefner J, Andrews J, Meng L, Bian A, Wolff AA. Relationships between riluzole and tirasemtiv levels on outcomes in the BENEFITS-ALS trial. Presented at the Presented at the 25th International Symposium on ALS/MND; December 5–7, 2014; Brussels, Belgium.
  • Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.
  • Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al. Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:481–8.
  • Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60:22–31.
  • Cudkowicz ME, Titus S, Kearney M, Yu H, Sherman A, Schoenfeld D, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:1083–91.
  • Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, et al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2013;12:1059–67.
  • Macchi Z, Wang Y, Moore D, Katz J, Saperstein D, Walk D, et al. A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: possible mitochondrial biomarker target engagement. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:345–52.
  • Andrews JA, Miller TM, Vijayakumar V, Stoltz R, James JK, Meng L, et al. CK-2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle Nerve. 2018;57:729–34.
  • Rudnicki SA, Andrews JA, Malik FI, Wolff AA, Day JW. Update of CY 5021: a phase 2 clinical trial of reldesemtiv, a fast skeletal muscle troponin activator (FSTA), for the potential treatment of spinal muscular atrophy. Presented at the Presented at CURE SMA; June 14–17, 2018; Dallas, TX.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.